Navamedic ASA Successfully Completes Acquisition of Dne Pharma
On July 15, 2025, Navamedic ASA announced the successful completion of its acquisition of the Norwegian company Dne Pharma AS, a transaction valued at approximately NOK 225 million (around USD 25 million). This monumental step marks Navamedic's strategic expansion into the growing sector of addiction treatment and highlights its commitment to enhancing public health solutions.
Overview of the Transaction
The acquisition, first announced on June 23, 2025, involves an asset purchase agreement where Navamedic pays NOK 185 million at closing, with an additional NOK 40 million contingent on achieving specific sales targets of the acquired product portfolio. Along with its product line, Navamedic gains access to Dne Pharma's team, essential contracts, intellectual property, licenses, and distribution agreements.
Dne Pharma's product offerings prominently feature several specialized medications, including
Ventizolve®, an intranasal naloxone spray that provides critical assistance in opioid overdose reversals,
Levopidon®, a formulation of levomethadone, and
Metadon Dne, utilized for opioid substitution therapies. This acquisition strategically positions Navamedic to enhance its reach and capabilities in addressing addiction issues, a significant public health concern.
Integration into Navamedic's Operations
The integration of Dne Pharma's business into Navamedic's existing framework is anticipated to be swift, utilizing its established commercial platform for rapid market access in the Nordic region and selected European markets. CEO Kathrine Gamborg Andreassen expressed enthusiasm regarding the acquisition's strategic fit, noting it represents a careful alignment with the company’s long-term growth objectives. "Thanks to excellent collaboration among all parties involved, this transaction was executed efficiently. We also appreciate the backing from Kistefos and the underwriters who made this possible," Andreassen remarked.
Financing the Acquisition
This acquisition has been financed through a combination of new debt, amounting to NOK 110 million from Nordea Bank, and the approval of a rights issue during an extraordinary general meeting held by Navamedic. The completion of the acquisition was facilitated by a bridge loan from Nordea, ensuring the swift transaction execution prior to the rights issue finalization.
Future Prospects
Geir Ove Engeset, the CEO of Dne Pharma, conveyed confidence about the future under Navamedic’s leadership. He expressed optimism that the Navamedic team would successfully advance the opioid substitution business that Dne Pharma has developed, particularly with products like Ventizolve, which are crucial in combating the opioid crisis.
About Navamedic ASA
Founded in 2006 and headquartered in Oslo, Norway, Navamedic ASA is dedicated to providing high-quality pharmaceutical products. The company focuses on improving quality of life through reliable services in both prescription and non-prescription health care sectors. Navamedic has a diverse product portfolio that targets current public health issues, including obesity and various chronic diseases. The company prides itself on its understanding of local healthcare needs, making it a preferred partner for international companies looking to expand in the Nordic and Benelux regions. You can learn more about their offerings and initiatives by visiting
www.Navamedic.com.
Conclusion
The acquisition of Dne Pharma by Navamedic marks a pivotal moment in the company's journey towards becoming a leader in the treatment of addiction and underscores its commitment to improving societal health outcomes. With an emphasis on innovative products and enhanced market access, Navamedic is poised to make a substantial impact in the public health arena.